LumiraDx Investor Presentation Deck
LumiraDx Today:
Transforming Community-based Healthcare
Next Generation POC
Diagnostic Company
Addressing the current limitations of legacy POC systems by bringing lab-comparable performance
to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership
Large Installed Base with
Global Commercial Reach
Manufacturing
Designed for Scale
Broad Menu and Pipeline
of Diagnostic Tests
Experienced
Management Team
lumiraDx™
25,000 instruments shipped to 105 countries across primary care, pharmacy, hospital emergency
departments, global health, and other settings
.
All current and future POC tests are developed on common strip design, enabling flexible, automated and
low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month
Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID).
50+ assays in three-year roadmap*
Fourth POC company for founding team. Management team has a successful track record
of diagnostic innovation and building / scaling companies in POC
Global Total Addressable Market: We estimate each test based on our current assumptions, including (a) the existing marketsizes. (b) central lab market that could move to POC;
and (c) expansion of diagnostic testing.
Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide
52View entire presentation